Furthermore, a large preclinical study showed that enzalutamide significantly reduced proliferation, migration, and invasion, while increasing apoptosis in 11 BC cell lines (three non-TN and eight TNBC); moreover, growth inhibition was dependent on the expression of AR, which is consistent with the findings of another research that involved four different non-LAR TNBC cell lines of the MSL, BL2, and mesenchymal-like subtypes demonstrating enzalutamide-mediated cell inhibition (80, 81). Here, AR is linked to breast cancer.